Provider review
Maves review
One of the lower entry figures here, covering both molecules without separating them.
A single floor cannot be true of both at the same cost, because the dual agonist costs more to compound.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Maves
From $89/mo, neither molecule priced separately
- Vs median
- $80/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The entry figure here is genuinely low, and the shape of the catalog explains some of why. Maves is built around performance and optimization rather than weight loss as a standalone concern — muscle, energy, sleep and longevity get equal billing with fat loss, and the GLP-1 line sits inside that range rather than being the whole business. If you want one prescriber handling several things at once that is a real convenience, and the quality claims are more specific than most: independent potency testing is asserted, not just licensing, and the state coverage is stated with its exclusions rather than rounded up. The pricing is where you have to be careful. One figure covers a product called simply GLP-1 treatments, and the site names both molecules elsewhere without attaching a price to either. Everywhere else that sells both publishes two numbers, because the dual agonist costs more to compound, which means one low floor cannot be true of both at the same price. Either it is the single-agonist number with the other dearer by an amount the page does not state, or it buys a configuration the page does not describe. No milligram sits behind it either, so if you are holding a deliberately small dose you have a low number you cannot attach to a quantity — a better problem than a high one, and still a problem.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want one prescriber covering muscle, energy and longevity alongside weight
- You want potency testing claimed specifically rather than licensing alone
- You are shopping on entry price and want one of the lower ones here in the set
Look elsewhere if
- You are choosing between the two molecules on cost. One floor covers both
- You need a ceiling. The figure is a starting point with none published
- You want the figure tied to an amount of drug. No dose sits behind it
What it actually costs
Price as published
A GLP-1 line from $89/month, priced as a single product rather than per molecule, alongside sermorelin from $120/month and NAD+ from $149/month · semaglutide and tirzepatide are both named as treatments on the site and neither is priced separately, so one floor covers whichever a patient receives and the two cannot be compared on cost · that figure is among the lower entry points published anywhere here, and it is a starting price with no ceiling and no dose behind it · medications are stated to be prepared by licensed U.S. pharmacies with independent quality and potency testing, and clinicians are stated to be licensed in all fifty states excluding U.S. territories · free expedited shipping and around-the-clock provider messaging are stated to be included, with the assessment described as taking two minutes
- Vs median
- $80/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. One floor covers a product called simply GLP-1 treatments, and both molecules are named elsewhere on the site without a price attached to either — so the entry figure cannot be true of both at the same cost, and which one it buys is unstated. The figure is among the lower entry points published anywhere here, which is a better problem than a high one and is still one, because nothing attaches it to a quantity of drug. ★ Quality claims go past licensing to independent potency testing, and state coverage is stated with its exclusions rather than rounded up. No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- One of the lower entry figures published anywhere here, visible before any assessment.
- Independent quality and potency testing is claimed, not just pharmacy licensing.
- State coverage is stated with its exclusions rather than rounded up.
Pharmacy, labs and oversight
Maves does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
1 of 4 published openly
What Maves publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Not published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
The entry figure here is genuinely low, and the shape of the catalog explains some of why. Maves is built around performance and optimization rather than weight loss as a standalone concern — muscle, energy, sleep and longevity get equal billing with fat loss, and the GLP-1 line sits inside that range rather than being the whole business. For a reader who wants one prescriber handling several things at once that is a real convenience, and the quality claims are more specific than most: independent potency testing is asserted, not just licensing, and the state coverage is stated with its exclusions rather than rounded up to fifty. The pricing is where a reader has to be careful. One figure covers a product called simply GLP-1 treatments, and the site names both molecules elsewhere without attaching a price to either. Everywhere else that sells both publishes two numbers, because the dual agonist costs more to compound, which means an $89 floor cannot be true of both at the same price. Either it is the semaglutide number with the other dearer by an amount the page does not state, or it buys a configuration the page does not describe. No milligram sits behind it either, so a reader holding a deliberately small dose has a low number they cannot attach to a quantity, which is a better problem than a high one and still a problem.
The honest cons
One floor covers both molecules, so the cheaper of the two cannot be identified.
- The figure is a starting point with no ceiling published.
- No dose sits behind it, so it cannot be matched to an amount of drug.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Maves is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#247 of 373
Ordered with the companies that pay us first, and Maves is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Microdosing semaglutide
- Microdosing tirzepatide
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.